GC | PE | |
(n = 121) | (n = 120) | |
Age (years) | ||
⩽70 | 92 (76%) | 97 (81%) |
>70 | 29 (24%) | 23 (19%) |
Median | 62 | 62.5 |
Range | 37–80 | 27–81 |
Sex | ||
Male | 68 (56%) | 68 (57%) |
Female | 53 (44%) | 52 (43%) |
ECOG performance status | ||
0 | 13 (11%) | 14 (12%) |
1 | 68 (56%) | 69 (58%) |
2 | 30 (25%) | 30 (25%) |
3 | 10 (8%) | 7 (6%) |
Stage | ||
Limited locally advanced/poor prognosis | 52 (43%) | 51 (43%) |
Extensive | 69 (57%) | 69 (58%) |
GC, gemcitabine and carboplatin; PE, cisplatin and etoposide.